Skip to main content
Signal8
Launch Terminal

BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

BridgeBio Pharma, Inc. logo

BridgeBio Pharma, Inc.

NASDAQ:BBIOHealthcare
+5.97%$74.95
AH$74.47-0.64%vs close
Mkt Cap$14.6B
Float160.36M
O/S194.8M
Vol
$ Vol
RVOL
Inst Own99.3%
SI12.5%
Earnings
Dilution
BridgeBio Pharma, Inc. logoNASDAQ:BBIO$74.95+5.97%
Upcoming Catalysts
  • BBP-418PDUFA
    limb-girdle muscular dystrophy type 2I/R9 (FKRP-related)
    Cash runway at this date: 4yr
    Nov 27, 2026in 25 days8-K
  • infigratinibPDUFA
    achondroplasia
    Cash runway at this date: 3yr
    Feb 4, 2027in 94 days8-K
  • oral infigratinibPDUFA
    achondroplasia in children
    Cash runway at this date: 3yr
    Feb 4, 2027in 94 days8-K
Phase Distribution
33 lead-sponsored trials·12 active·9 completed
Phase 17
Phase 1/21
Phase 28
Phase 2/32
Phase 311
Phase 41
Not applicable3
(10 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Recent Deals
  • BayerMILESTONE
    $75M upfrontSep 30, 2026
    BEYONTTRA
  • BayerMILESTONE
    $75M upfrontJan 1, 1970
    acoramidis (BEYONTTRA)
Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Recruiting

    Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

    Acoramidis (AG10) oral tablet

    Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis +2

    Enrollment
    150
    Start
    Jul 2026est.
    Primary Completion
    Aug 2030est.
    Completion
    Nov 2030est.
    NCT07695701
  • Phase 3
    Terminated

    Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

    BGJ398, Gemcitabine

    Advanced Cholangiocarcinoma, FGFR2 Gene Mutation

    Enrollment
    48
    Start
    Dec 2019
    Primary Completion
    Mar 2023
    Completion
    Mar 2023
    NCT03773302
  • Phase 3
    Completed

    Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

    acoramidis, Placebo Oral Tablet

    Amyloidosis, Amyloid Cardiomyopathy +3

    Enrollment
    632
    Start
    Mar 2019
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT03860935
  • Phase 3
    Terminated

    Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

    Infigratinib, Placebo

    Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer

    Enrollment
    39
    Start
    Mar 2020
    Primary Completion
    Feb 2023
    Completion
    Feb 2023
    NCT04197986
  • Phase 3
    Withdrawn

    Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

    AG10, Placebo

    Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

    Enrollment
    0
    Start
    Oct 2020
    Primary Completion
    Mar 2024est.
    Completion
    Apr 2024est.
    NCT04418024
  • Phase 3
    Withdrawn

    Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

    Acoramidis

    Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

    Enrollment
    0
    Start
    Sep 2021
    Primary Completion
    Sep 2026est.
    Completion
    Oct 2026est.
    NCT04882735
  • Phase 3
    Active, not recruiting

    Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

    Acoramidis (AG10)

    Amyloid Cardiomyopathy, Transthyretin-Related

    Enrollment
    389
    Start
    Oct 2021
    Primary Completion
    Apr 2028est.
    Completion
    May 2028est.
    NCT04988386
  • Phase 3
    Active, not recruiting

    Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

    Encaleret

    Autosomal Dominant Hypocalcemia (ADH)

    Enrollment
    67
    Start
    Jan 2023
    Primary Completion
    Aug 2025
    Completion
    Aug 2029est.
    NCT05680818
  • Phase 3
    Completed

    A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

    Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day

    Achondroplasia

    Enrollment
    114
    Start
    Nov 2023
    Primary Completion
    Dec 2025
    Completion
    Dec 2025
    NCT06164951
  • Phase 3
    Recruiting

    Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

    Acoramidis, Placebo oral tablet

    Amyloidosis, Amyloid Cardiomyopathy +4

    Enrollment
    587
    Start
    May 2025
    Primary Completion
    Oct 2031est.
    Completion
    Dec 2032est.
    NCT06563895
  • Phase 3
    Not yet recruiting

    To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

    Acoramidis (AG10)

    Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial +8

    Enrollment
    250
    Start
    Nov 2026est.
    Primary Completion
    Nov 2037est.
    Completion
    Dec 2037est.
    NCT07116473
  • Phase 3
    Recruiting

    Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism

    Encaleret, Placebo

    Hypoparathyroidism, Chronic Hypoparathyroidism

    Enrollment
    160
    Start
    Aug 2026est.
    Primary Completion
    Jan 2028est.
    Completion
    Jan 2033est.
    NCT07805356
  • Phase 2/3
    Enrolling by invitation

    An Interventional Study of Infigratinib in Children With Hypochondroplasia

    infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day

    Hypochondroplasia

    Enrollment
    24
    Start
    Apr 2025
    Primary Completion
    Jan 2027est.
    Completion
    Jan 2027est.
    NCT06873035
  • Phase 2/3
    Recruiting

    Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

    Encaleret

    Autosomal Dominant Hypocalcemia Type 1 (ADH1)

    Enrollment
    28
    Start
    Jan 2026
    Primary Completion
    Dec 2028est.
    Completion
    Dec 2030est.
    NCT07080385
  • Phase 2
    Terminated

    A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

    BGJ398 (infigratinib)

    Advanced Cholangiocarcinoma, FGFR2 Gene Mutation

    Enrollment
    143
    Start
    Jul 2014
    Primary Completion
    Mar 2021
    Completion
    Feb 2022
    NCT02150967
  • Phase 2
    Completed

    Study of AG10 in Amyloid Cardiomyopathy

    AG10, Placebo Oral Tablet

    Familial ATTR-CM (ATTRm-CM, or FAC), Wild-type ATTR-CM (ATTRwt-CM)

    Enrollment
    49
    Start
    Apr 2018
    Primary Completion
    Oct 2018
    Completion
    Oct 2018
    NCT03458130
  • Phase 2
    Terminated

    Open-Label Study of AG10 in Patients With Cardiomyopathy

    Acoramidis

    Amyloid Cardiomyopathy

    Enrollment
    47
    Start
    Aug 2018
    Primary Completion
    Sep 2025
    Completion
    Sep 2025
    NCT03536767
  • Phase 2
    Completed

    Study of Infigratinib in Children With Achondroplasia

    Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg

    Achondroplasia

    Enrollment
    84
    Start
    Mar 2020
    Primary Completion
    Oct 2024
    Completion
    Oct 2024
    NCT04265651
  • Phase 2
    Completed

    Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

    Encaleret

    Autosomal Dominant Hypocalcemia (ADH), Autosomal Dominant Hypocalcemia Type 1 (ADH1)

    Enrollment
    13
    Start
    Sep 2020
    Primary Completion
    Sep 2023
    Completion
    Sep 2023
    NCT04581629
  • Phase 2
    Enrolling by invitation

    Extension Study of Infigratinib in Children With Achondroplasia (ACH)

    Infigratinib, Infigratinib

    Achondroplasia

    Enrollment
    325
    Start
    Dec 2021
    Primary Completion
    Dec 2031est.
    Completion
    Feb 2032est.
    NCT05145010
  • Phase 2
    Recruiting

    Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

    Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration

    Achondroplasia

    Enrollment
    77
    Start
    Nov 2025
    Primary Completion
    Mar 2030est.
    Completion
    Mar 2032est.
    NCT07169279
  • Phase 2
    Enrolling by invitation

    Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

    Infigratinib

    Hypochondroplasia

    Enrollment
    135
    Start
    Apr 2026
    Primary Completion
    May 2036est.
    Completion
    May 2036est.
    NCT07393373
  • Phase 1/2
    Terminated

    First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations

    VT30

    Venous Malformation, Lymphatic Malformation +1

    Enrollment
    15
    Start
    Oct 2020
    Primary Completion
    Apr 2022
    Completion
    Apr 2022
    NCT04409145
  • Phase 1
    Completed

    Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10

    AG10 oral tablet, Placebo Oral Tablet

    Amyloid Cardiomyopathy, Transthyretin-Related

    Enrollment
    56
    Start
    Sep 2017
    Primary Completion
    Feb 2018
    Completion
    May 2018
    NCT03294707
  • Phase 1
    Terminated

    First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors

    BBP-398 (Formerly known as IACS-15509)

    Tumor, Solid

    Enrollment
    72
    Start
    Nov 2020
    Primary Completion
    Mar 2024
    Completion
    Jul 2024
    NCT04528836

1-25 of 33

Search ClinicalTrials.gov for “BridgeBio Pharma”